Sargent Bickham Lagudis LLC Gilead Sciences, Inc. Transaction History

Sargent Bickham Lagudis LLC

$1.22 Billion
Q4 2022

A detailed history of Sargent Bickham Lagudis LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Sargent Bickham Lagudis LLC holds 2,692 shares of GILD stock, worth $248,767. This represents 0.02% of its overall portfolio holdings.

Number of Shares

2,692

Previous 2,692 -0.0%

Holding current value

$248,767

Previous $166,000 39.16%

% of portfolio

0.02%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 27, 2022	SELL	$59.54 - $68.01 $20,481 - $23,395	-344 Reduced 11.33%	2,692 $166,000
Q2 2022 Jul 13, 2022	BUY	$57.72 - $65.01 $19,855 - $22,363	344 Added 12.78%	3,036 $188,000
Q1 2022 Apr 27, 2022	SELL	$57.92 - $72.58 $37,937 - $47,539	-655 Reduced 19.57%	2,692 $160,000
Q4 2021 Jan 18, 2022	SELL	$64.88 - $73.64 $12,651 - $14,359	-195 Reduced 5.51%	3,347 $243,000
Q3 2021 Nov 05, 2021	SELL	$67.69 - $73.03 $302,506 - $326,371	-4,469 Reduced 55.79%	3,542 $247,000
Q2 2021 Jul 19, 2021	BUY	$63.47 - $69.35 $60,233 - $65,813	949 Added 13.44%	8,011 $552,000
Q1 2021 May 24, 2021	BUY	$60.0 - $68.46 $73,860 - $84,274	1,231 Added 21.11%	7,062 $456,000
Q4 2020 May 24, 2021	SELL	$56.65 - $64.55 $69,736 - $79,461	-1,231 Reduced 17.43%	5,831 $340,000
Q4 2020 May 24, 2021	BUY	$56.65 - $64.55 $124,743 - $142,139	2,202 Added 45.31%	7,062 $456,000
Q3 2020 Sep 01, 2021	BUY	$62.1 - $78.08 $31,919 - $40,133	514 Added 11.83%	4,860 $307,000
Q2 2020 Sep 07, 2021	SELL	$72.34 - $84.0 $13,599 - $15,792	-188 Reduced 4.15%	4,346 $334,000
Q1 2020 Sep 07, 2021	BUY	$62.63 - $80.22 $10,584 - $13,557	169 Added 3.87%	4,534 $339,000
Q4 2019 Sep 14, 2021	BUY	$61.62 - $67.78 $2,033 - $2,236	33 Added 0.76%	4,365 $284,000
Q3 2019 Sep 14, 2021	SELL	$62.51 - $69.0 $6,813 - $7,521	-109 Reduced 2.45%	4,332 $275,000
Q2 2019 Sep 13, 2021	SELL	$61.87 - $69.38 $17,818 - $19,981	-288 Reduced 6.09%	4,441 $300,000
Q1 2019 Sep 13, 2021	BUY	$62.53 - $70.05 $7,128 - $7,985	114 Added 2.47%	4,729 $307,000
Q4 2018 Sep 13, 2021	SELL	$60.54 - $79.0 $11,563 - $15,089	-191 Reduced 3.97%	4,615 $289,000
Q3 2018 Sep 13, 2021	BUY	$71.28 - $78.92 $51,179 - $56,664	718 Added 17.56%	4,806 $371,000
Q2 2018 Sep 13, 2021	BUY	$64.88 - $75.68 $21,280 - $24,823	328 Added 8.72%	4,088 $290,000
Q1 2018 Sep 13, 2021	SELL	$72.84 - $88.8 $3,642 - $4,440	-50 Reduced 1.31%	3,760 $283,000
Q4 2017 Sep 13, 2021	BUY	$71.15 - $83.52 $84,455 - $99,138	1,187 Added 45.25%	3,810 $273,000
Q3 2017 Sep 13, 2021	BUY	$72.11 - $85.47 $360 - $427	5 Added 0.19%	2,623 $213,000
Q2 2017 Sep 13, 2021	BUY	N/A	6 Added 0.23%	2,618 $185,000
Q1 2017 Sep 13, 2021	SELL	N/A	-519 Reduced 16.58%	2,612 $177,000
Q4 2016 Sep 13, 2021	SELL	N/A	-178 Reduced 5.38%	3,131 $224,000
Q3 2016 Sep 13, 2021	BUY	N/A	100 Added 3.12%	3,309 $262,000
Q2 2016 Sep 07, 2021	BUY	N/A	79 Added 2.52%	3,209 $268,000
Q1 2016 Sep 07, 2021	BUY	N/A	3,130	3,130 $287,000

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sargent Bickham Lagudis LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sargent Bickham Lagudis LLC with notifications on news.

Account

Sargent Bickham Lagudis LLC Gilead Sciences, Inc. Transaction History